Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs

British Journal of Clinical Pharmacology

Volumn 47, Issue 3, 1999, Pages 307-313

  De Abajo, Francisco José ^a   García Rodríguez, Luis Alberto ^b  

^a Area de Farmacovigilancia   (Spain)

^b Ctro Espanol de Metrologia   (Spain)

Author keywords

Antihistamines; Ventricular arrhythmias

Indexed keywords

ACRIVASTINE; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; LORATADINE; TERFENADINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ARRHYTHMIA; ASTEMIZOLE; CASE-CONTROL STUDIES; CETIRIZINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; INFANT; INFANT, NEWBORN; INFORMATION SYSTEMS; LORATADINE; MALE; MIDDLE AGED; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TERFENADINE; TRIPROLIDINE;

EID: 0033061972     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00885.x     Document Type: Article

References (27)

1. 1 Monahan BP, Ferguson CL, Killeavy ES, ct al. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788-2790.
2. 2 MacConnell TJ, Stanners AJ. Torsades de pointes complicating treatment with terfenadine. Br Med J 1991; 302: 1469.
3. 3 Mathews DR, McNutt B, Okerholm R, et al. Torsades de pointes occurring in association with terfenadine use. JAMA 1991; 266: 2375-2376.
4. 4 Woosley RL, Chen Y, Freiman JP, Gillis RA. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532-1536.
5. 5 Woosley RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36: 233-252.
6. 6 Yun C, Okerholm RA, Guengerich FP. Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P45034A in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21: 403-409.
7. 7 Sorkin EM, Heel RC. Terfenadine: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29: 34-56.
8. 8 Estelle F, Simons R. H1-Receptor Antagonists-Comparative tolerability and safety. Drug Safety 1994; 10: 350-380.
9. 9 Mastey V. Torsades de pointes in patients receiving terfenadine or astemizol. Drug and Devices Information Line. Harvard School of Public Health. http://www.hsph.harvard.edu/organizations /DDIL/ddil.html.
10. 10 Nightingale SL. Warnings issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992; 268: 705.
11. 11 Pratt CM, Hertz RP, Ellis BE, Crowell SP, Louv W, Moye L. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994; 73: 346-352.
12. 12 Hanranhan JP, Choo PW, Carlson W, Greineder D, Faich G, Platt R. Terfenadine-associated ventricular arrythmias and QTc interval prolongation. A retrospective cohort comparison with other antihistamines among members of a health maintenance organization. Ann Epidemiol 1995; 5: 201-209.
13. 13 FDA Talk paper. FDA proposes to withdraw Seldane approval. Jan 13, 1997. http://www.fda.gov/bbs/topics/ANSWERS/ ANS00780.html.
14. 14 The European Agency for the Evaluation of Medicinal Products. Final Opinion of the Committe for Proprietary Medicinal Products pursuant to article 12 of Council Directive 75/319/EEC as amended for Terfenadine containing products. London, 25 February, 1997. CPMP/255/98-EN.
15. 15 Linquist M, Edwards IR. Risks of non-sedating antihistamines. Lancet 1997; 349: 1322.
16. 16 García Rodríguez LA, Pérez Gutthann S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 1998; 45: 419-425.
17. 17 Jick H, Jick SS, Derby L. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J 1991; 302: 766-768.
18. 18 Walker AM. Observation and Inference. An introduction to the methods of epidemiology. Epidemiology Resources: Newton Lower Falls, 1991. pp. 73-85.
19. 19 Craft TM. Torsades de pointes after astemizole overdose. Br Med J 1986; 292: 660-668.
20. 20 Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsades de pointes ventricular tachychardia associated with astemizole overdose. Br J Clin Pract 1988; 42: 257-259.
21. 21 Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ. Astemizole-induced torsades de pointes. Lancet 1988; ii: 624.
22. 22 Desager JP, Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 1995; 28: 419-432.
23. 23 Staffa JA, Jones JK, Gable CB, Verspeelt JP, Amery WK. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 1995; 17: 1062-1077.
24. 24 Lacerda AE, Roy ML, Lewis EW, Rampe D. Interactions of the nonsedating anthistamine loratadine with a Kv1.5-type potassium channel cloned from human heart. Mol Pharmacol 1997; 52: 314-322.
25. 25 Delpón E, Valenzuela C, Pilar Gay, Franqueza L, Snyders DJ, Tamargo J. Block of human cardiac Kv1.5 channels by loratadine: voltage-, time-, and use-dependent block at concentrations above therapeutic levels. Cardiovasc Res 1997; 35: 341-350.
26. 26 Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996; 275: 1339-1341.
27. 27 Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997; 350: 1115-1116.